CONCORD

CONtrol of COmmunity-acquired MRSA: Rationale and Development of counteractions

 Coordinatore UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

 Organization address address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX

contact info
Titolo: Dr.
Nome: Susan
Cognome: Zwaagstra
Email: send email
Telefono: +31 88 755 3017
Fax: +31 88 755 5413

 Nazionalità Coordinatore Netherlands [NL]
 Totale costo 3˙937˙759 €
 EC contributo 2˙994˙192 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-B
 Funding Scheme CP-FP
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-01-01   -   2012-06-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT

 Organization address address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX

contact info
Titolo: Dr.
Nome: Susan
Cognome: Zwaagstra
Email: send email
Telefono: +31 88 755 3017
Fax: +31 88 755 5413

NL (UTRECHT) coordinator 679˙471.00
2    UNIVERSITEIT VAN AMSTERDAM

 Organization address address: SPUI 21
city: AMSTERDAM
postcode: 1012WX

contact info
Titolo: Dr.
Nome: Floyd
Cognome: R.A. Wittink
Email: send email
Telefono: +3120525 7937
Fax: +3120 525 7762

NL (AMSTERDAM) participant 525˙257.00
3    DANMARKS TEKNISKE UNIVERSITET

 Organization address address: Anker Engelundsvej 1, Building 101A
city: KONGENS LYNGBY
postcode: 2800

contact info
Titolo: Prof.
Nome: Peter
Cognome: Dyrsting
Email: send email
Telefono: +45 72 34 61 38
Fax: +45 72 34 60 01

DK (KONGENS LYNGBY) participant 353˙092.00
4    THE UNIVERSITY OF EDINBURGH

 Organization address address: OLD COLLEGE, SOUTH BRIDGE
city: EDINBURGH
postcode: EH8 9YL

contact info
Titolo: Ms.
Nome: Angela
Cognome: Noble
Email: send email
Telefono: +44 131 650 9024
Fax: +44 131 650 9023

UK (EDINBURGH) participant 311˙308.00
5    NOVOLYTICS LIMITED

 Organization address address: BACLAYS VENTURE CENTRE UNIT 26
city: COVENTRY
postcode: CV4 7EZ

contact info
Titolo: Mr.
Nome: Sandy
Cognome: Primrose
Email: send email
Telefono: +44 1494 474226
Fax: +44 2476 575048

UK (COVENTRY) participant 235˙552.00
6    NARODOWY INSTYTUT LEKOW

 Organization address address: ULICA CHELMSKA 30/34
city: WARSZAWA
postcode: 00 725

contact info
Titolo: Ms.
Nome: Renata
Cognome: Cellmer
Email: send email
Telefono: -8514350
Fax: -8410626

PL (WARSZAWA) participant 235˙200.00
7    UNIVERSITE LYON 1 CLAUDE BERNARD

 Organization address address: BOULEVARD DU 11 NOVEMBRE 1918 NUM43
city: VILLEURBANNE CEDEX
postcode: 69622

contact info
Titolo: Dr.
Nome: Javier
Cognome: Olaiz
Email: send email
Telefono: -698039
Fax: -698048

FR (VILLEURBANNE CEDEX) participant 226˙800.00
8    UNIVERSITEIT UTRECHT

 Organization address address: Heidelberglaan 8
city: UTRECHT
postcode: 3584 CS

contact info
Titolo: Dr.
Nome: J.A.
Cognome: Manders
Email: send email
Telefono: +31 30 253 2435
Fax: +31 30 253 2333

NL (UTRECHT) participant 225˙000.00
9    INSTITUTO DE TECNOLOGIA QUIMICA E BIOLOGICA - UNIVERSIDADE NOVA DE LISBOA

 Organization address address: "Avenida da Republica, Estacao Agronomica Nacional"
city: OEIRAS
postcode: 2784-505

contact info
Titolo: Dr.
Nome: Margarida
Cognome: Martinez
Email: send email
Telefono: -4468929
Fax: -214468963

PT (OEIRAS) participant 202˙512.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

aureus    epidemiology    until    farm    countries    ecological    confined    successful    mathematical    hospitals    recently    models    concord    patients    infections    staphylococcus    sequenced    environment    infection    contrast    types    isolates    ca    mrsa    scientists    livestock    physiological    community    methicillin    gene    transmission    fa    found    tested    mechanisms    small    strategies    resistant    bacteria    genetic    knock    combat    exist    rationale    outs    genome    differences    resistance    pig    strains   

 Obiettivo del progetto (Objective)

'Until recently, methicillin-resistant Staphylococcus aureus (MRSA) were confined to hospitals (HA-MRSA). However, community- and farm-associated MRSA (CA-and FA-MRSA) has developed as an important cause of infections. No strategies exist to combat these MRSA. CONCORD is aimed at explaining the ecological success in the community and the farm environment of CA- and FA-MRSA in contrast to HA-MRSA in order to facilitate the rationale and development of effective strategies against CA- and FA-MRSA. Epidemiology of CA-MRSA is complex and incomplete. To obtain both a more complete description of the epidemiology of CA-MRSA and recent isolates small scale surveillance will be performed among patients in the 20 most populous EU countries, pig farms in major pig exporting countries and important veal calve raising countries. Genomics data for CA-MRSA are limited and non-existent for FA-MRSA. Successful adaptation of MRSA to a new environment supposes either the acquisition of novel properties or the differential expression of genes already present. Only 2 CA-MRSA have been fully sequenced and the UMCU has sequenced a FA-MRSA. Whole genome sequencing, comparative genome hybridization and transcriptomics will be used to understand the genetic adaptations of MRSA in the community. The contribution of putative virulence factors to pathogenicity will be studied by knock-outs and complemented strains of these knock-outs. The strains will be tested in in vitro and ex vivo models to establish their physiological role. Mathematical modelling is an important tool to manage infection control. A few models exist that evaluate measures to reduce transmission of HA-MRSA or CA-MRSA in jails. No models are available for FA-MRSA. Modelling will provide both fundamental insights on MRSA epidemiology as well as specific recommendations or testable hypotheses for human and veterinary clinical practice. The potential of intervention strategies to combat CA- and FA-MRSA will be determined.'

Introduzione (Teaser)

Until recently, methicillin-resistant Staphylococcus aureus (MRSA) strains were confined to hospitals (HA-MRSA). The emergence of community and farm MRSA strains has triggered scientists to investigate the mechanisms underlying the ecological success of S. aureus.

Descrizione progetto (Article)

The first epidemics of MRSA in patients without prior history of hospitalisations were described in the 1990s. Since then, community- and farm-associated MRSA (CA-MRSA and FA-MRSA, respectively) have developed as an important cause of infections. MRSA isolates carry the methicillin resistance mecA gene on a chromosome cassette also referred to as SCCmec. From a genetic perspective, most HA-MRSA types belong to clonal complex 5, while CA-MRSA is genetically much more diverse.

The successful establishment of CA-MRSA in the community constitutes the most alarming change in the epidemiology of MRSA. It is, therefore, of paramount importance to understand the implicated mechanisms involved to be able to manage or prevent bacterial infection.

Based on this, the EU-funded 'Control of community-acquired MRSA: Rationale and development of counteractions' (CONCORD) project aimed to investigate CA-MRSA colonisation. To this end, the consortium concentrated on the genetic and transcriptional differences among MRSA strains in Europe, and assessed how they could influence bacteria physiology.

Following the collection and molecular typing of a large set of European MRSA isolates, researchers concluded that some resistant bacteria types originated in Europe, while others were imported. Interestingly, the majority of these strains demonstrated resistance to other antibiotics and livestock-associated (LA) MRSA strains showed additional resistance to zinc, a property attributed to the csrC gene.

Dissemination studies revealed a reciprocal dissemination pattern between humans and animals, which, however, occurred at a very low rate. Scientists also tested the hypothesis that small changes in the genetic content of S. aureus might lead to physiological differences and found that alteration of the beta-toxin gene affected host adaptation.

High antibiotic pressure was found to have driven ribosomal RNA loss in HA-MRSA and cystic fibrosis isolates. Scientists believe that although these events facilitated resistance development, they reduced the fitness of the strains and their subsequent success in the community. In contrast, CA-MRSA retained their rRNA copies and were therefore more fit and capable of spreading in the community.

Through novel mathematical models, CONCORD researchers generated the opportunity to study between-farm and between-hospital MRSA transmissions. These tools could be employed by countries to estimate the transmission potential of MRSA strains, assess public and livestock risk and take appropriate countermeasures.

Altri progetti dello stesso programma (FP7-HEALTH)

TARGETAMD (2012)

"Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration (AMD)"

Read More  

GAMEXP (2009)

"Genomic approaches to metabolite exploitation from Xenorhabdus, Photorhabdus"

Read More  

PARCIVAL (2012)

Partner Network for a Clinically Validated Multi-Analyte Lab-on-a-Chip Platform

Read More